Breaking News

MannKind Ends Afrezza License with Sanofi

January 5, 2016

Will transition development and commercialization to MannKind

MannKind Corp. has terminated its license and collaboration agreement with Sanofi-aventis U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The companies will transition the development and commercialization of Afrezza from Sanofi to MannKind within 180 days.
 
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the Sanofi collaboration.

Related Searches:

blog comments powered by Disqus

Related Online Exclusives

Related Features

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments
    View More
  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development
    View More
  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer
    View More

Related Breaking News